A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED-CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

被引：6
|
作者：
Ratziu, V. [1 ]
De Ledinghen, V. [2 ]
Oberti, F. [3 ]
Mathurin, P. [4 ]
Wartelle-Bladou, C. [5 ]
Renou, C. [6 ]
Spenard, J. [7 ,8 ]
机构：
[1] Hop La Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[2] Hop Haut Leveque, Serv Hepatogastroenterol, Pessac, France
[3] CHU Angers, Serv Hepatogastroenterol, Angers, France
[4] Ctr Hosp Reg & Univ Lille, Hop Huriez, Serv Malad Appareil Digestif, F-59037 Lille, France
[5] CHG Pays Aix, Serv Hepatogastroenterol, Aix En Provence, France
[6] CH Hyeres, Unite Hepatogastroenterol, Hyeres, France
[7] Axcan Pharma, Mt St Hilaire, PQ, Canada
[8] Univ Montreal, Dept Pharmacol, Fac Med, Montreal, PQ H3C 3J7, Canada
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)60049-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
47
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [21] Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
    Harrison, Stephen A.
    Ruane, Peter J.
    Freilich, Bradley L.
    Neff, Guy
    Patil, Rashmee
    Behling, Cynthia A.
    Hu, Chen
    Fong, Erica
    de Temple, Brittany
    Tillman, Erik J.
    Rolph, Timothy P.
    Cheng, Andrew
    Yale, Kitty
    NATURE MEDICINE, 2021, 27 (07) : 1262 - +
  • [22] Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis
    Safadi, Rifaat
    Braun, Marius
    Francis, Adi
    Milgrom, Yael
    Massarwa, Muhammad
    Hakimian, David
    Hazou, Wadi
    Issachar, Assaf
    Harpaz, Zivit
    Farbstein, Motti
    Itzhak, Inbal
    Lev-Cohain, Naama
    Bareket-Samish, Avital
    Silverman, Michael H.
    Fishman, Pnina
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (11-12) : 1405 - 1415
  • [23] Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial
    Noto, Davide
    Petta, Salvatore
    Giammanco, Antonina
    Spina, Rossella
    Cabibbi, Daniela
    Porcasi, Rossana
    Caldarella, Rosalia
    Ciaccio, Marcello
    Muratore, Roberto
    Cefalu, Angelo B.
    Craxi, Antonio
    Averna, Maurizio
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (05) : 1288 - 1291
  • [24] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Harrison, Stephen A.
    Bashir, Mustafa R.
    Guy, Cynthia D.
    Zhou, Rong
    Moylan, Cynthia A.
    Frias, Juan P.
    Alkhouri, Naim
    Bansal, Meena B.
    Baum, Seth
    Neuschwander-Tetri, Brent A.
    Taub, Rebecca
    Moussa, Sam E.
    LANCET, 2019, 394 (10213): : 2012 - 2024
  • [25] Does Ursodeoxycholic Acid Work with Nondiabetic Patients with Non-Alcoholic Steatohepatitis?
    Bektas, Atilla
    Ulusoy, Meltem
    Dagalp, Kemal
    KONURALP TIP DERGISI, 2020, 12 (01): : 44 - 49
  • [26] Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
    Ceriani, R
    Brunati, S
    Morini, L
    Sacchi, E
    Colombo, G
    HEPATOLOGY, 1998, 28 (04) : 386A - 386A
  • [27] A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients
    Fouda, A.
    Abdelaziz, A. E.
    Hussien, M.
    Ali, A. A.
    Abdelkawy, K. S.
    Elbarbry, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (23) : 7449 - 7459
  • [28] DISEASE PROGRESSION IN TAIWANESE NON-ALCOHOLIC STEATOHEPATITIS PATIENTS: SUBGROUP ANALYSIS OF THE PLACEBO PATIENTS IN A DOUBLE-BLIND RANDOMIZED TRIAL
    Yeh, Ming-Lun
    Huang, Jee-Fu
    Huang, Chung-Feng
    Dai, Chia-Yen
    Yu, Ming-Lung
    Chuang, Wan Long
    HEPATOLOGY, 2023, 78 : S950 - S951
  • [29] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong, Matthew James
    Gaunt, Piers
    Aithal, Guruprasad P.
    Barton, Darren
    Hull, Diana
    Parker, Richard
    Hazlehurst, Jonathan M.
    Guo, Kathy
    Abouda, George
    Aldersley, Mark A.
    Stocken, Deborah
    Gough, Stephen C.
    Tomlinson, Jeremy W.
    Brown, Rachel M.
    Huebscher, Stefan G.
    Newsome, Philip N.
    LANCET, 2016, 387 (10019): : 679 - 690
  • [30] Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
    Kessoku, Takaomi
    Imajo, Kento
    Kobayashi, Takashi
    Ozaki, Anna
    Iwaki, Michihiro
    Honda, Yasushi
    Kato, Takayuki
    Ogawa, Yuji
    Tomeno, Wataru
    Kato, Shingo
    Higurashi, Takuma
    Yoneda, Masato
    Kirikoshi, Hiroyuki
    Kubota, Kazumi
    Taguri, Masataka
    Yamanaka, Takeharu
    Usuda, Haruki
    Wada, Koichiro
    Kobayashi, Noritoshi
    Saito, Satoru
    Nakajima, Atsushi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (11): : 996 - 1007
12345